V. Diehl, R. Thomas, and D. Re, Part II: Hodgkin's lymphoma???diagnosis and treatment, The Lancet Oncology, vol.5, issue.1, pp.19-26, 2004.
DOI : 10.1016/S1470-2045(03)01320-2

E. Campo, S. Swerdlow, N. Harris, S. Pileri, H. Stein et al., The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, issue.19, pp.5019-5051, 2011.
DOI : 10.1182/blood-2011-01-293050

R. Siegel, K. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin. 2015 Feb, vol.65, issue.1, pp.5-29, 2015.

D. Eichenauer, A. Engert, M. André, M. Federico, T. Illidge et al., Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, issue.suppl 3, pp.70-75, 2014.
DOI : 10.1093/annonc/mdu181

A. Engert and A. Younes, Hodgkin Lymphoma Available from, Hematologic Malignancies), pp.978-981, 2015.

D. Hasenclever and V. Diehl, A Prognostic Score for Advanced Hodgkin's Disease, New England Journal of Medicine, vol.339, issue.21, pp.1506-1520, 1998.
DOI : 10.1056/NEJM199811193392104

T. Lister, D. Crowther, S. Sutcliffe, E. Glatstein, G. Canellos et al., Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting., Journal of Clinical Oncology, vol.7, issue.11, pp.1630-1636, 1989.
DOI : 10.1200/JCO.1989.7.11.1630

D. Duggan, G. Petroni, J. Johnson, J. Glick, R. Fisher et al., Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin???s Disease: Report of an Intergroup Trial, Journal of Clinical Oncology, vol.21, issue.4, pp.607-621, 2003.
DOI : 10.1200/JCO.2003.12.086

V. Diehl, J. Franklin, M. Pfreundschuh, B. Lathan, U. Paulus et al., Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease, New England Journal of Medicine, vol.348, issue.24, pp.2386-95, 2003.
DOI : 10.1056/NEJMoa022473

M. Meignan, S. Barrington, E. Itti, A. Gallamini, C. Haioun et al., Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma, Leuk Lymphoma, vol.55, issue.1, pp.3-531, 2012.

M. Hutchings, N. Mikhaeel, P. Fields, T. Nunan, and A. Timothy, Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma, Annals of Oncology, vol.16, issue.7, pp.1160-1168, 2005.
DOI : 10.1093/annonc/mdi200

M. Hutchings, A. Loft, M. Hansen, L. Pedersen, T. Buhl et al., FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, vol.107, issue.1, pp.52-61, 2006.
DOI : 10.1182/blood-2005-06-2252

A. Evens, M. Hutchings, and V. Diehl, Treatment of Hodgkin lymphoma: the past, present, and future, Nature Clinical Practice Oncology, vol.11, issue.9, pp.543-56, 2008.
DOI : 10.1038/ncponc1186

A. Stathis and A. Younes, The new therapeutical scenario of Hodgkin lymphoma, Annals of Oncology, vol.26, issue.10, pp.2026-2059, 2015.
DOI : 10.1093/annonc/mdv256

G. Canellos, S. Rosenberg, J. Friedberg, T. Lister, and V. Devita, Treatment of Hodgkin Lymphoma: A 50-Year Perspective, Journal of Clinical Oncology, vol.32, issue.3, pp.163-171, 2014.
DOI : 10.1200/JCO.2013.53.1194

A. Cuccaro, F. Bartolomei, E. Cupelli, E. Galli, M. Giachelia et al., PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA, Mediterranean Journal of Hematology and Infectious Diseases, vol.6, issue.1, p.2014053, 2014.
DOI : 10.4084/mjhid.2014.053

R. Schmitz, J. Stanelle, M. Hansmann, and R. Küppers, Pathogenesis of Classical and Lymphocyte-Predominant Hodgkin Lymphoma, Annual Review of Pathology: Mechanisms of Disease, vol.4, issue.1, pp.151-74, 2009.
DOI : 10.1146/annurev.pathol.4.110807.092209

M. Schumacher, R. Schmitz, V. Brune, E. Tiacci, C. Doring et al., Mutations in the genes coding for the NF-??B regulating factors I??B?? and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma, Haematologica, vol.95, issue.1, pp.153-160, 2010.
DOI : 10.3324/haematol.2009.010157

M. Slovak, V. Bedell, Y. Hsu, D. Estrine, N. Nowak et al., Molecular Karyotypes of Hodgkin and Reed-Sternberg Cells at Disease Onset Reveal Distinct Copy Number Alterations in Chemosensitive versus Refractory Hodgkin Lymphoma, Clinical Cancer Research, vol.17, issue.10, pp.3443-54, 2011.
DOI : 10.1158/1078-0432.CCR-10-1071

J. Reichel, A. Chadburn, P. Rubinstein, L. Giulino-roth, W. Tam et al., Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood, Feb, vol.12125, issue.7, pp.1061-72, 2015.

J. Martín-subero, S. Gesk, L. Harder, T. Sonoki, P. Tucker et al., Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood, Feb, vol.1599, issue.4, pp.1474-1481, 2002.

S. Joos, C. Menz, G. Wrobel, R. Siebert, S. Gesk et al., Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2, Blood, vol.99, issue.4, 2002.
DOI : 10.1182/blood.V99.4.1381

S. Dubois, P. Viailly, S. Mareschal, E. Bohers, P. Bertrand et al., Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study, Clinical Cancer Research, vol.22, issue.12
DOI : 10.1158/1078-0432.CCR-15-2305

URL : https://hal.archives-ouvertes.fr/hal-01442496

S. Mareschal, S. Dubois, P. Viailly, P. Bertrand, E. Bohers et al., Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes, Chromosomes and Cancer, vol.110, issue.3, 2015.
DOI : 10.1002/gcc.22328

URL : https://hal.archives-ouvertes.fr/hal-01237083

O. Ritz, C. Guiter, F. Castellano, K. Dorsch, J. Melzner et al., Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma, Blood, vol.114, issue.6, pp.1236-1278, 2009.
DOI : 10.1182/blood-2009-03-209759

URL : https://hal.archives-ouvertes.fr/inserm-00411059

C. Steidl and R. Gascoyne, The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood, pp.2659-69, 2011.

M. Fornerod, M. Ohno, M. Yoshida, and I. Mattaj, CRM1 is an export receptor for leucine-rich nuclear export signals. Cell, pp.1051-60, 1997.

M. Fukuda, S. Asano, T. Nakamura, M. Adachi, M. Yoshida et al., CRM1 is responsible for intracellular transport mediated by the nuclear export signal, Nature, vol.390, issue.6657, pp.308-319, 1997.

L. Pemberton and B. Paschal, Mechanisms of Receptor-Mediated Nuclear Import and Nuclear Export. Traffic, pp.187-98, 2005.

K. Nguyen, M. Holloway, and R. Altura, The CRM1 nuclear export protein in normal development and disease, Int J Biochem Mol Biol, vol.3, issue.2, pp.137-51, 2012.

T. Monecke, A. Dickmanns, and R. Ficner, Allosteric control of the exportin CRM1 unraveled by crystal structure analysis, FEBS Journal, vol.24, issue.18, pp.4179-94, 2014.
DOI : 10.1111/febs.12842

S. Jeromin, S. Weissmann, C. Haferlach, F. Dicker, K. Bayer et al., SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients, Leukemia, vol.98, issue.1, pp.108-125, 2014.
DOI : 10.1038/leu.2013.263

D. Lin, J. Hao, Y. Nagata, L. Xu, L. Shang et al., Genomic and molecular characterization of esophageal squamous cell carcinoma, Nature Genetics, vol.31, issue.5, pp.467-73, 2014.
DOI : 10.1093/nar/gkt439

J. Gunawardana, F. Chan, A. Telenius, B. Woolcock, R. Kridel et al., Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma, Nature Genetics, vol.362, issue.4, pp.329-364
DOI : 10.1038/ng.2900

J. Etchin, T. Sanda, M. Mansour, A. Kentsis, J. Montero et al., KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia, British Journal of Haematology, vol.21, issue.1, pp.117-144
DOI : 10.1111/bjh.12231

R. Lapalombella, Q. Sun, K. Williams, L. Tangeman, S. Jha et al., Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood, pp.4621-4655, 2012.

J. Kuruvilla, J. Byrd, and J. Flynn, The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) [Abstract 396, 56th ASH Annual Meeting, 2014.

L. Diaz and A. Bardelli, Liquid Biopsies: Genotyping Circulating Tumor DNA, Journal of Clinical Oncology, vol.32, issue.6, pp.579-86, 2014.
DOI : 10.1200/JCO.2012.45.2011

E. Bohers, P. Viailly, S. Dubois, P. Bertrand, C. Maingonnat et al., Somatic mutations of cell-free circulating DNA detected by Next Generation Sequencing reflect the genetic changes in both Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B- Cell Lymphoma tumors at the time of diagnosis, Haematologica, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01132460

P. Vandenberghe, I. Wlodarska, T. Tousseyn, L. Dehaspe, D. Dierickx et al., Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study, The Lancet Haematology, vol.2, issue.2, pp.55-65, 2015.
DOI : 10.1016/S2352-3026(14)00039-8

Y. Oki, S. Neelapu, M. Fanale, L. Kwak, L. Fayad et al., Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach, British Journal of Haematology, vol.14, issue.5, pp.689-93
DOI : 10.1111/bjh.13349

V. Camus, N. Vasseur, E. Bohers, S. Dubois, S. Mareschal et al., Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.122, issue.9, 2016.
DOI : 10.1182/blood.V98.9.2762

S. Dubois, S. Mareschal, J. Picquenot, P. Viailly, E. Bohers et al., Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?, Oncotarget, vol.6, issue.18, 2015.
DOI : 10.18632/oncotarget.3154

B. Cheson, B. Pfistner, M. Juweid, R. Gascoyne, L. Specht et al., Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.579-86, 2007.
DOI : 10.1200/JCO.2006.09.2403

H. Kanzler, M. Hansmann, U. Kapp, J. Wolf, V. Diehl et al., Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient, Blood, vol.87, issue.8, pp.3429-3465, 1996.

M. Schaadt, V. Diehl, H. Stein, C. Fonatsch, and H. Kirchner, Two neoplastic cell lines with unique features derived from Hodgkin's disease, International Journal of Cancer, vol.41, issue.6, pp.723-754, 1980.
DOI : 10.1002/ijc.2910260605

V. Diehl, M. Pfreundschuh, C. Fonatsch, H. Stein, M. Falk et al., Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications, Cancer Surv, vol.4, issue.2, pp.399-419, 1985.

B. Hock and D. Hart, Cellular protein profiles of the Hodgkin's disease cell lines L428, KM-H2 and HDLM-2: A comparative study, Leukemia Research, vol.16, issue.3, pp.253-63, 1992.
DOI : 10.1016/0145-2126(92)90063-D

U. Kapp, A. Düx, E. Schell-frederick, N. Banik, M. Hummel et al., Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice, Annals of Oncology, vol.5, issue.suppl 1, pp.121-127, 1994.
DOI : 10.1093/annonc/5.suppl_1.S121

P. Möller, A. Mader, T. Barth, and S. Brüderlein, A new cell line derived from a primary refractory classical Hodgkin lymphoma]. Pathol, pp.317-325, 2008.

Y. Liu, A. Razak, F. Terpstra, M. Chan, F. Saber et al., The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing, Leukemia, vol.28, issue.11, pp.2248-51, 2014.
DOI : 10.1038/ng.2469

A. Traverse-glehen, S. Pittaluga, P. Gaulard, L. Sorbara, M. Alonso et al., Mediastinal Gray Zone Lymphoma, The American Journal of Surgical Pathology, vol.29, issue.11, pp.1411-1432, 2005.
DOI : 10.1097/01.pas.0000180856.74572.73

URL : https://hal.archives-ouvertes.fr/hal-01471621

J. Bond, A. Bergon, A. Durand, I. Tigaud, X. Thomas et al., Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood, pp.3023-3028, 2014.

R. Guieze, P. Robbe, R. Clifford, S. De-guibert, B. Pereira et al., Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood, pp.2110-2117, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01263113

X. Puente, M. Pinyol, V. Quesada, L. Conde, G. Ordóñez et al., Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.25, issue.7354, pp.101-106, 2011.
DOI : 10.1038/nature10113

S. Mareschal, S. Dubois, P. Viailly, P. Bertrand, E. Bohers et al., Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes, Chromosomes and Cancer, vol.110, issue.3, 2015.
DOI : 10.1002/gcc.22328

URL : https://hal.archives-ouvertes.fr/hal-01237083

E. Chiu, T. Gold, V. Fettig, M. Levasseur, and D. Cressman, Identification of a Nuclear Export Sequence in the MHC CIITA, The Journal of Immunology, vol.194, issue.12, pp.6102-6113, 2015.
DOI : 10.4049/jimmunol.1402026

L. Xie, A. Ushmorov, F. Leithauser, H. Guan, C. Steidl et al., FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood, Apr, vol.12119, issue.15, pp.3503-3514, 2012.

Y. Hao, B. Chapuy, S. Monti, H. Sun, S. Rodig et al., Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo, Clinical Cancer Research, vol.20, issue.10, pp.2674-83, 2014.
DOI : 10.1158/1078-0432.CCR-13-3007

S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition, 2008.

L. Xerri, P. Parc, R. Bouabdallah, J. Camerlo, and J. Hassoun, PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease, The Journal of Pathology, vol.56, issue.2, pp.189-94, 1995.
DOI : 10.1002/path.1711750206

W. Chen, Y. Chen, O. Kamel, C. Koo, and L. Weiss, p53 mutations in Hodgkin's disease. Lab Investig J Tech Methods Pathol, pp.519-546, 1996.

E. Maggio, E. Stekelenburg, A. Van-den-berg, and S. Poppema, TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus, International Journal of Cancer, vol.16, issue.1, pp.60-66, 2001.
DOI : 10.1002/ijc.1438

S. Salipante, A. Adey, A. Thomas, C. Lee, Y. Liu et al., Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma, Genes Chromosomes Cancer, 2009.

M. Weniger, I. Melzner, C. Menz, S. Wegener, A. Bucur et al., Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation, Oncogene, vol.28, issue.18, pp.2679-84, 2006.
DOI : 10.1038/sj.onc.1209151

O. Ritz, K. Rommel, K. Dorsch, E. Kelsch, J. Melzner et al., STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL), Oncotarget, vol.4, issue.7, pp.1093-102, 2013.
DOI : 10.18632/oncotarget.1149

R. Schmitz, M. Hansmann, V. Bohle, J. Martin-subero, S. Hartmann et al., (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma, The Journal of Experimental Medicine, vol.161, issue.5, pp.981-990, 2009.
DOI : 10.1159/000112062

X. Liu, H. Yu, Y. W. Zhou, X. Lu, H. Shi et al., Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma, Cancer Genetics and Cytogenetics, vol.197, issue.2, pp.152-159, 2010.
DOI : 10.1016/j.cancergencyto.2009.11.005

F. Emmerich, S. Theurich, M. Hummel, A. Haeffker, M. Vry et al., Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells, The Journal of Pathology, vol.376, issue.3, pp.413-433, 2003.
DOI : 10.1002/path.1454

J. Lennerz, K. Hoffmann, A. Bubolz, D. Lessel, C. Welke et al., Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma, Oncotarget, vol.6, issue.30, pp.29097-110, 2015.

E. Maggio, . Van-den, A. Berg, D. De-jong, A. Diepstra et al., Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma, The American Journal of Pathology, vol.162, issue.1, pp.29-35, 2003.
DOI : 10.1016/S0002-9440(10)63795-9

J. Kanakry, H. Li, L. Gellert, M. Lemas, W. Hsieh et al., Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial, Blood, vol.121, issue.18, pp.3547-53, 2013.
DOI : 10.1182/blood-2012-09-454694

K. Jones, F. Vari, C. Keane, P. Crooks, J. Nourse et al., Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma, Clinical Cancer Research, vol.19, issue.3, pp.731-773
DOI : 10.1158/1078-0432.CCR-12-2693

Y. Elshimali, H. Khaddour, M. Sarkissyan, Y. Wu, and J. Vadgama, The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients, International Journal of Molecular Sciences, vol.14, issue.9, pp.18925-58, 2013.
DOI : 10.3390/ijms140918925

M. Beau-faller, M. Gaub, A. Schneider, X. Ducrocq, G. Massard et al., Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients, International Journal of Cancer, vol.945, issue.3, pp.361-70, 2003.
DOI : 10.1002/ijc.11079

G. Xie, A. Hou, L. Li, Y. Gao, and S. Cheng, Quantification of plasma DNA as a screening tool for lung cancer, Chin Med J (Engl), vol.117, issue.10, pp.1485-1493, 2004.

A. Szpechcinski, J. Chorostowska-wynimko, R. Struniawski, W. Kupis, P. Rudzinski et al., Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease, British Journal of Cancer, vol.66, issue.3, pp.476-83, 2015.
DOI : 10.1038/bjc.2015.225

F. Jardin, Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: a LYSA Study. 57th ASH, oral abstract #129, Blood, issue.23, p.126, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01300803

M. Tubiana, M. Henry-amar, P. Carde, J. Burgers, M. Hayat et al., Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials, Blood, vol.73, issue.1, pp.1964-198747, 1989.